Shots:

• The approval is based on P-III PRISM-2 study results assessing Palynziq (pegvaliase-pqpz- 20mg qd or 40mg qd) in patients in ratio (2:1) with high level of phenylalanine (Phe)
• The P-III PRISM-2 study resulted in maintaining blood Phe level vs PBO in patients
• Palynziq (pegvaliase-pqpz- SC) is an enzyme substitution therapy of phenylalanine hydroxylase (PAH) enzyme helping in breaking down of Phe

Ref: Biomarin | Image: Biomarin